GlassScriptPhysician profile
Francis William Mueller
NPI 1164493409
$2,303.34
in general payments reported to CMS, 2019-2025
23 companies · $694 in 2025
The $694 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $456 · 2020: $137 · 2021: $225 · 2022: $57.58 · 2023: $206 · 2024: $529 · 2025: $694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,428.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $415.40 | 2024-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $373.55 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $268.44 | 2019-2025 | |
| Lilly USA, LLC | $174.48 | 2020-2025 | Zepbound, Jardiance, Emgality |
| Pfizer INC. | $143.96 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $133.98 | 2020-2025 | Breztri |
| Teva Pharmaceuticals USA, INC. | $132.49 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $129.71 | 2021 | |
| Amarin Pharma, INC. | $107.15 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $81.80 | 2019-2025 | Gardasil 9, Capvaxive |
| Astellas Pharma US INC | $47.02 | 2021-2024 | Veozah |
| Allergan, INC. | $45.50 | 2019 | |
| Amgen INC. | $41.85 | 2019-2020 | |
| Glaxosmithkline, LLC. | $39.42 | 2019-2024 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.54 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $24.59 | 2024 | Edarbi |
| Dexcom, INC. | $19.05 | 2025 | Dexcom G6 Transmitter |
| Viatris Specialty LLC | $18.80 | 2025 | Yupelri |
| Currax Pharmaceuticals LLC | $17.70 | 2023 | Onzetra Xsail, Contrave |
| Circassia INC. | $16.98 | 2019 | |
| Therapeuticsmd, INC. | $16.88 | 2019 | |
| Exact Sciences Corporation | $16.11 | 2025 | The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $12.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francis Mueller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.